SOFIE has selected an automated radiosynthesizer for standardized production of its Ga-68 FAPI and F-18 FAPI. This will facilitate production at SOFIE’s facilities for supply to its clinical trial sites.

US-based FAPI-46 and FAPI-74 Tox studies have been completed by Covance at its Indianapolis facility.

ABX is SOFIE’s partner of choice for our FAPI precursor production. ABX has successfully completed the manufacture and shipment of the first stocks of FAPI precursor material, enabling our distribution of precursor and reference standards under MTAs to multiple approved users in the US and EU.

Uwe Haberkorn, MD, PhD

Stefano Fanti, MD

• Chairman of FAPI Scientific Advisory Board

• Head of Nuclear Medicine, University of Bologna

 Frederick Giesel, MD, MBA

• Vice Chair of Nuclear Medicine, Department of Nuclear Medicine, University Hospital Heidelberg

• Full Professor at Osaka University, Osaka Japan and expert in the field oncological theranostics

 Clemens Kratochwil, MD

• Attending and Director, Therapy Unit, Department of Nuclear Medicine at the University of Heidelberg

 Jens Siveke, MD

• Head of the Division of Solid Tumor Translational Oncology (DKFZ/DKTK partner site Essen)

• Full Professor in the Department of Medical Oncology at the West German Cancer Center, University Hospital Essen

Johannes Czernin, MD

• Nuclear Medicine and Internal Medicine

• Chief, Ahmanson Translational Imaging Division at UCLA

Ken Herrmann, MD, MBA

• Chair of Nuclear Medicine at the University of Duisburg-Essen